Tumors of the salivary glands account for no more than 5% of all neoplasms of the head and neck. About 70% of all benign neoplasms of the salivary glands are pleomorphic. One of the rare localizations of pleomorphic adenoma is the larynx. Not more than 30 cases of laryngeal localization of pleomorphic adenoma are described in the literature currently. The article presents the result of organ-preserving surgical treatment of the patient with large pleomorphic adenoma of the larynx.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/otorino202288041110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent Pleomorphic Adenoma Presenting as a Giant Parapharyngeal Mass.
Ear Nose Throat J
January 2025
Department of Otolaryngology-Head and Neck Surgery, Al-Bairuni University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria.
Article Synopsis
- Pleomorphic adenoma (PA) is a common benign tumor of the salivary glands, often recurs and can extend into the parapharyngeal space (PPS), complicating treatment.
- A 45-year-old male with a history of limited PA excision presented with a growing neck mass and related symptoms; MRI revealed a large tumor in the PPS.
- Surgical removal involved a specialized neck approach, and the patient received postoperative radiotherapy, emphasizing the complexities and careful planning required for effective management of PPS tumors.
A review of submandibular gland extirpation in an Australian quaternary referral centre: aetiologies and trends over 35 years.
ANZ J Surg
December 2024
Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Background: Submandibular gland pathology is common but rarely reported. This study was performed to evaluate demographic, pathological, and survival outcomes associated with submandibular gland extirpation.
Methods: Retrospective analysis of patients treated in a single quaternary-care institution between 1989 and 2022 was performed.
Nerve dissection technique for excision of parotid tumors: Outcomes controlling for tumor size and location.
Am J Otolaryngol
December 2024
Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Purpose: We examined operative efficiency, rate of facial nerve paresis, and post-operative outcomes in patients undergoing retrograde (RGD) vs anterograde dissection (AGD) of the facial nerve controlling for tumor location.
Methods: Single-institution, retrospective analysis of patients with benign parotid tumors undergoing superficial parotidectomy with facial nerve dissection over a six-year period. Operative and pathology reports were reviewed to classify tumor size, location in relation to facial nerve branches, and technique for facial nerve dissection.
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFUnexpected cause of dyspnea: A case of pleomorphic adenoma in the trachea.
Radiol Case Rep
February 2025
Department of Radiology, National Institute of Oncology, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Rabat, Morocco.
Pleomorphic adenoma (PA) is the most common benign histological form of salivary gland tumors, particularly in the parotid gland, primarily affecting women between the ages of 40 and 60. However, its occurrence in the trachea is very rare. This article reports the case of a 48-year-old woman presenting with progressive dyspnea and weight loss, initially suspected of having a pulmonary embolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!